$CAMT

Andorn Karni Yarl sold $928K of CAMT

Andorn Karni Yarl sold 5,532 shares of CAMTEK LTD (CAMT) at an average of $167.79 ($164.40–$172.74, $0.93M total) across 3 trades over 2026-08-13 to 2026-08-14.

Original reporting
SEC EDGAR · Andorn Karni Yarl
Published Aug 17, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 17, 2026, 1:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CAMT
Neutral
medium confidence
Mentioned
$CAMT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CAMTNeutralLow
01

Why it matters

The disclosure updates the insider activity record and may influence short-term sentiment, but it does not provide new operating or financial information.

02

Market read

Traders may monitor CAMT for any clustering of insider selling, but the filing alone is unlikely to drive a major repricing without additional catalysts.

03

What to watch

The article does not state tax, diversification, or personal liquidity drivers, and it does not confirm whether the sale was part of a broader planned program beyond noting 'No' for a pre-arranged 10b5-1 plan.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-17, covering sales executed 2026-08-13 to 2026-08-14

Background

This is an SEC Form 4 insider transaction for CAMTEK, reported by a director.

Company-level read

Ticker impact

$CAMTNeutralMedium confidence
Context

CAMTEK director Andorn Karni Yarl sold $928,200 of CAMT shares in open-market trades dated 2026-08-13 to 2026-08-14.

Expected impact

Likely limited, short-lived sentiment impact; watch for follow-through only if additional insider selling or new fundamentals emerge.

Evidence & confidence

Form 4 shows a completed sale (5,532 shares) with no 10b5-1 plan stated, but the article provides no earnings, guidance, or operational catalyst.

Market effects

No sector-wide implications are provided; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Insider sales can be routine liquidity events and may not signal negative outlook, especially without any accompanying negative company news in the filing.

Key entities

  • CAMTEK LTD

    Company whose shares were sold by a director, per SEC Form 4.

  • Andorn Karni Yarl

    Director who executed open-market sales totaling $928,200.28.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CAMTMed

CAMTEK LTD (CAMT): Financial results for FY

CAMTEK LTD (CAMT) furnished an SEC Form 6-K — earnings release. Yes ☐ No ☒ SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. This Form 6-K, including all exhibits hereto, is hereby incorporated by r

$ESLTMed

Tue: Rate cut lifts market

The Tel Aviv Stock Exchange rose after the Bank of Israel cut interest rates to 3.25%. The Tel Aviv 35 Index gained 0.22%, while Dimri led gains with a 5.47% rise. OPC Energy fell 4.67%, the biggest decline. Key movers included Elbit Systems, Teva, and Ormat, which rose, and Camtek and Tower Semiconductor, which fell.

$CRDOMed

3 Under-the-Radar AI Stocks Wall Street Is Missing

Credo Technology (CRDO) reported Q4 2026 revenue of $437M, up 157% YoY, with guidance for 80% YoY growth in 2027. Astera Labs (ALAB) saw Q2 2026 revenue of $392.4M, up 104% YoY, with Scorpio X series ramping ahead of schedule. Camtek (CAMT) reported Q2 2026 revenue of $133.24M, up 8% YoY, with a strong order book extending into 2027.

$CAMTMedAI 8/10

Camtek (CAMT) Posted Record Q2 Revenue, Is The AI Upside Already Priced In?

Camtek (CAMT) reported record Q2 revenue of $600M+ year-to-date, driven by AI-related advanced packaging demand. The company issued upbeat Q3 guidance, contributing to a 17.55% monthly and 48.74% year-to-date stock price increase. Analysts debate its valuation, with some seeing it as 8.3% undervalued at $171.80, while others suggest it's overvalued based on discounted cash flow models.